Smiggles - Your antepenultimate statement doesn't seem to match most of the other points in your post. Margins are absolutely critical to our success so anything that threatens this area is a concern to me. The biggest disappointment for me in 2013 was the end of talk from UNS about device-drug patent extensions. The UNS story remains good but device-drug patent extension would have packed a powerful revenue punch. It also would have been a robust catalyst for moving many approved drugs online VERY quickly. Fortunately, we still have a good business case in numerous areas.
UNS Price at posting:
76.0¢ Sentiment: Hold Disclosure: Held
